Perampanel, a non-competitive AMPA glutamate receptor antagonist, is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older.
Perampanel
Specifications
Human
Oral
In Development
FEATURED Products
Related Media
New Product Development
Where our FDA approved laboratory begins developing products, formulating and validating methods to ensure quality.
Compliance Audits
Where we audit and champion our partner factories to exceed cGMP standards set by authorities.
Regulatory Services
Where all submissions are filed with the knowledge and experience of our 550+ worldwide approvals on record.